Drug interactions
Fostemsavir + Liposomal doxorubicin
Severity: Moderate
Fostemsavir and Liposomal doxorubicin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Fostemsavir's active metabolite temsavir inhibits BCRP, and doxorubicin is a BCRP substrate. Exposure to doxorubicin could therefore rise modestly, increasing the risk of myelosuppression and cardiotoxicity. Clinical data are lacking.
What this interaction means in plain words
Fostemsavir and Liposomal doxorubicin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Fostemsavir belongs to Anti Virals; Liposomal doxorubicin belongs to Oncology.
Why it happens
Temsavir inhibits BCRP efflux transport, which may reduce doxorubicin elimination.
What to do
Monitor blood counts and cardiac function more closely. Consider a doxorubicin dose reduction if toxicity emerges.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Fostemsavir and Liposomal doxorubicin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Other interactions of Fostemsavir
- Apalutamide + Fostemsavir Contraindicated
- Carbamazepine + Fostemsavir Contraindicated
- Enzalutamide + Fostemsavir Contraindicated
- Fostemsavir + Mitotane Contraindicated
- Fostemsavir + Phenytoin Contraindicated
- Fostemsavir + Rifampicin Contraindicated
Frequently asked questions
Can I take Fostemsavir with Liposomal doxorubicin?
MediHelp rates the interaction as moderate. Fostemsavir and Liposomal doxorubicin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Fostemsavir's active metabolite temsavir inhibits BCRP, and doxorubicin is a BCRP substrate. Exposure to doxorubicin could therefore rise modestly, increasing the risk of myelosuppression and cardiotoxicity. Clinical data are lacking.
How serious is the interaction between Fostemsavir and Liposomal doxorubicin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and cardiac function more closely. Consider a doxorubicin dose reduction if toxicity emerges.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
